HiloProbe, based in Umeå, secures SEK 3 million in funding from existing owners for sales initiation. The capital injection aims to attract more investment and reach a break-even point. The company is close to a breakthrough with ColoNode, a reagent kit for analyzing lymph nodes in colorectal cancer patients.
Swedish biotech company HiloProbe has reached a significant milestone after the results of a prospective multicenter study conducted in collaboration with Umeå University and eight Swedish hospitals were published in the International Journal of Cancer. The study results show that HiloProbe's ColoNode kit improves colon cancer diagnostics and can help more patients survive.
Thomas Busch has extensive experience in the life science industry. Now he's appointed new Chairman of the Board at HiloProbe.
Umeå University has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode's benefits and usefulness in colon cancer.
Umeå-based HiloProbe AB has entered a partnership with the major international company Biocartis Group NV. This is a strategically important step for HiloProbe in its aim to reach out globally with its colorectal cancer test product, ColoNode®.